KHIRON Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Europe and Latin America, continues to demonstrate its market dominance in the UK’s medical cannabis industry with cannabis sales volume growth of 240% in Q1 2022 compared to the entire 2021 year.
This growth is generated by Khiron’s end-to-end solution of government regulation, supply chain, distribution, and clinics prescribing Khiron’s medical cannabis products.
With a population of almost 67 million, the UK has a potential of at least 1.5% medical cannabis patients1. Khiron addresses the great potential in the UK with its medical cannabis products and clinical services, which are increasingly used by patients and medical practitioners. In late 2021, Khiron opened its first European Zerenia™ Medical Cannabis Clinics in the UK, offering telemedicine service to patients around the country, and contributing to the Company’s patient acquisition and retention growth.
“Today, Khiron has already established market leadership in the UK with it first two products on the market, and its KHIRON 20/1 THC-predominant strain is one of the best-selling medically prescribed products in the UK market,” comments Franziska Katterbach, President of Khiron Europe.
“In Q1 2022, we expect to surpass our first 1 million CAD in revenues in the UK, and as we expand our portfolio, and increase our patient base, Khiron will consolidate its market leadership within the country. In 2021, Europe accounted for 33% of Khiron’s medical cannabis revenues, at more than 1.5 million CAD. In Q1 2022 and beyond, Europe will represent over 50% of Khiron’s cannabis revenues, strengthening Khiron’s position as a leader in the global medical cannabis market.”
